This purified Mouse Anti-MDM2 Monoclonal Antibody recognizes the human MDM2 protein. Because MDM2 can bind to and inactivate the transcriptional activity of p53, over-expression of MDM2 protein has been detected in a variety of human tumors, and appears to result from gene amplification, increased transcript level, and enhanced translation. Validated applications for this Mouse Anti-MDM2 Monoclonal Antibody are western blotting, immunohistochemistry (frozen, FFPE), immunoprecipitation, and immunofluorescence.
• Applications: Validated applications for Mouse MDM2 Monoclonal Antibody are western blotting, immunohistochemistry (frozen,FFPE), immunoprecipitation, and immunofluorescence.
• Host Species and Isotype: The host species and isotype of this MDM2 monoclonal antibody is mouse IgG2bκ.
• Reactivity: Detects human MDM2 protein.
• Clone ID of Monoclonal Antibody (mAb): The monoclonal antibody clone is IF2.
• Product Size: Mouse Anti-MDM2 Monoclonal Antibody is available in a 50 µg pack size.
The MDM2 (murine double minute 2) proto-oncogene was originally identified as an amplified gene in a mouse tumor cell line. Subsequently, over-expression of MDM2 was shown to produce tumors in athymic mice. In a separate set of studies, the 90 kDa MDM2 was found to bind and inactivate the transcriptional activity of the p53 protein. p53 was also identified as the major target for MDM2 during embryonic development by virtue of the fact that the lethal effects produced by knocking out MDM2 could be reversed by the simultaneous deletion of p53. Interestingly, the MDM2 gene itself is a transcriptional target for p53, and induction of p53 transcriptional activity results in increased MDM2 mRNA and protein levels. Therefore, it appears that a MDM2-p53 feedback loop serves to keep the growth suppressive functions of p53 in check during the normal cell cycle. In addition, recent studies have implicated MDM2 in regulating cell proliferation via p53-independent pathways. This is based on evidence that MDM2 can interact with Rb, E2F-1 and DP1.
Because MDM2 can bind to and inactivate the transcriptional activity of p53, over expression of MDM2 protein has been detected in a variety of human tumors, and appears to result from gene amplification, increased transcript level, and enhanced translation. In a recent study of 3889 samples from 28 human tumor types, the overall frequency of MDM2 amplification was estimated to be 7%. Gene amplification was observed in 19 tumor types, and the highest frequency was observed in soft tumors (20%), followed by osteosarcomas (16%) and esophageal carcinomas (13%).